AstraZeneca Lung Cancer Therapy Combination Shows Promise in Advanced Study
4 Articles
4 Articles
AstraZeneca-Hutchmed drug combination shows promise in advanced lung cancer study - Regional Media News
Sept 1 (Reuters) - AstraZeneca and China's Hutchmed said on Tuesday that a late-stage trial of a combination of their cancer drugs Tagrisso and Orpathys significantly improved progression-free survival when given early for a type of lung cancer. Cancer therapies make up nearly half of [...]
AstraZeneca lung cancer therapy combination shows promise in advanced study
Sept 1 (Reuters) - AstraZeneca said on Tuesday that a Chinese late-stage trial of a combination of its cancer drugs Tagrisso and Orpathys significantly improved progression-free survival when given as a first-line treatment for a type of...
A study showed a significant improvement in the time in which patients remain without worsening of the disease. New data from an advanced stage clinical study create prospects for the therapeutic treatment of a specific form of advanced non-small cell lung cancer. AstraZeneca and China's Hutchmed announced that the combination of osimertinib and savoritinib achieved the key goal of a large clinical trial, as it significantly improved progression…
AstraZeneca announces that Tagrisso plus Orpathys demonstrated a statistically significant and highly clinically meaningful improvement in progression-free survival (PFS) in first-line treatment of so-called MET-amplified EGFR-mutated lung cancer.
Coverage Details
Bias Distribution
- 50% of the sources are Center, 50% of the sources lean Right
Factuality
To view factuality data please Upgrade to Premium
